Nanoplatin: Phase I/II data

Data from 17 evaluable patients in the Phase I portion of an open-label, Singaporean and Taiwanese Phase I/II trial showed that Nanoplatin produced 2 partial responses and 9 cases of stable disease. Median OS was 12.3 months and median progression-free survival (PFS) was 5.1 months. The maximum tolerated dose (MTD) of Nanoplatin was 120 mg/m 2. Patients received 30, 60, 90 or 120 mg/m 2 Nanoplatin once every 3 weeks in combination with 1,000 mg/m 2 gemcitabine twice every 3 weeks. Data were presented at the European Society for Medical Oncology meeting in Vienna. ...